tetano
Editor, Senior Moderator
Biosens Bioelectron
. 2025 Jul 7:287:117762.
doi: 10.1016/j.bios.2025.117762. Online ahead of print. Hemagglutinin docking analysis-based visual detection of antiviral therapeutic efficacy of umifenovir against influenza virus
Jinyoung Kim[SUP] 1 [/SUP], Jong-Woo Lim[SUP] 2 [/SUP], Hyun-Ouk Kim[SUP] 3 [/SUP], Joowon Park[SUP] 4 [/SUP], Eunji Jeong[SUP] 4 [/SUP], Chaewon Park[SUP] 4 [/SUP], Geunseon Park[SUP] 4 [/SUP], Minjoo Yeom[SUP] 2 [/SUP], Daesub Song[SUP] 2 [/SUP], Eun-Kyung Lim[SUP] 5 [/SUP], Seungjoo Haam[SUP] 6 [/SUP]
Affiliations
The rapid evolution of viruses poses a significant threat to global health, as evidenced by recent pandemics. Umifenovir (Arbidol®), a broad-spectrum antiviral drug, has demonstrated potential in treating various viral infections. This study aimed to assess the antiviral mechanism of umifenovir against influenza A virus (IAV), specifically its interaction with hemagglutinin (HA), using umifenovir-modified gold nanoparticles (umi-GNPs). Umi-GNPs have been applied to various IAV subtypes, including H1N1, H3N2, H4N6, H6N8, and H9N2. Our results demonstrate that umifenovir effectively inhibits viral replication in all tested subtypes at a viral titer of 10[SUP]4.5[/SUP] 50 % egg infective dose (EID[SUB]50[/SUB])/mL. Additionally, the aggregation of umi-GNPs with viruses pre-bound to umifenovir was suppressed, indicating that umi-GNPs bind to a specific region of the viral protein. These findings indicate that umi-GNPs can serve as novel agents for visually determining umifenovir resistance in IAV.
Keywords: Antiviral resistance; Hemagglutinin molecular docking; Influenza A virus; Umifenovir; Visual detection.
. 2025 Jul 7:287:117762.
doi: 10.1016/j.bios.2025.117762. Online ahead of print. Hemagglutinin docking analysis-based visual detection of antiviral therapeutic efficacy of umifenovir against influenza virus
Jinyoung Kim[SUP] 1 [/SUP], Jong-Woo Lim[SUP] 2 [/SUP], Hyun-Ouk Kim[SUP] 3 [/SUP], Joowon Park[SUP] 4 [/SUP], Eunji Jeong[SUP] 4 [/SUP], Chaewon Park[SUP] 4 [/SUP], Geunseon Park[SUP] 4 [/SUP], Minjoo Yeom[SUP] 2 [/SUP], Daesub Song[SUP] 2 [/SUP], Eun-Kyung Lim[SUP] 5 [/SUP], Seungjoo Haam[SUP] 6 [/SUP]
Affiliations
- PMID: 40639140
- DOI: 10.1016/j.bios.2025.117762
The rapid evolution of viruses poses a significant threat to global health, as evidenced by recent pandemics. Umifenovir (Arbidol®), a broad-spectrum antiviral drug, has demonstrated potential in treating various viral infections. This study aimed to assess the antiviral mechanism of umifenovir against influenza A virus (IAV), specifically its interaction with hemagglutinin (HA), using umifenovir-modified gold nanoparticles (umi-GNPs). Umi-GNPs have been applied to various IAV subtypes, including H1N1, H3N2, H4N6, H6N8, and H9N2. Our results demonstrate that umifenovir effectively inhibits viral replication in all tested subtypes at a viral titer of 10[SUP]4.5[/SUP] 50 % egg infective dose (EID[SUB]50[/SUB])/mL. Additionally, the aggregation of umi-GNPs with viruses pre-bound to umifenovir was suppressed, indicating that umi-GNPs bind to a specific region of the viral protein. These findings indicate that umi-GNPs can serve as novel agents for visually determining umifenovir resistance in IAV.
Keywords: Antiviral resistance; Hemagglutinin molecular docking; Influenza A virus; Umifenovir; Visual detection.